Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.
Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.
The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.
Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.
Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.
Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.
On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.
Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.
As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.
Boston Scientific's recent presentation at EuroPCR 2021 highlighted the positive performance of the ACURATE neo2 Aortic Valve System. Data from the Early neo2 and ITAL-neo Registries showed low rates of paravalvular leakage (1.3%) and permanent pacemaker implementation (6%). Additionally, the ACURATE neo2 demonstrated a 56% reduction in aortic regurgitation compared to its predecessor. The device has received CE Mark approval and is currently under evaluation in the U.S. under an IDE trial for patients with aortic stenosis.
Boston Scientific Corporation (NYSE: BSX) announced its participation in two upcoming investor conferences: the 2021 Bank of America Health Care Conference on May 11, 2021, and the 2021 UBS Global Healthcare Virtual Conference on May 25, 2021. Executives including Dan Brennan and Jeff Mirviss will engage in Q&A sessions at both conferences. Live webcasts will be available for investors and can be accessed through the company's investor relations website. This activity reflects Boston Scientific's continued engagement with investors and commitment to transparency.
Boston Scientific reported Q1 2021 net sales of $2.752 billion, an increase of 8.2% year-over-year. GAAP net income rose to $327 million, or $0.23 per share, compared to $11 million, or $0.01 per share, last year. The company exceeded guidance, with adjusted EPS at $0.37 versus the forecasted $0.28 to $0.34. Growth was seen across segments, particularly MedSurg and Cardiovascular, and strong performance in emerging markets at 16%. Regulatory approvals were received for key products, including TheraSphere and Ranger systems.
Boston Scientific Corporation (NYSE: BSX) will host a conference call on April 28, 2021, at 8:00 a.m. EDT to discuss its financial results for the first quarter ending March 31, 2021. The call will be led by Mike Mahoney, CEO, and Dan Brennan, CFO. A news release with the financial results will precede the call on the same day. Additionally, on May 5, 2021, key executives will participate in a Q&A at the Truist Securities 2021 Life Sciences Summit. Webcasts for both events will be available online.
Boston Scientific has announced positive results from the TARGET study of TheraSphere™ Y-90 Glass Microspheres, presented at the Society of Interventional Radiology meeting on March 25, 2021. This therapy aims to treat hepatocellular carcinoma (HCC), the most common liver cancer, showing a median overall survival of 20.3 months. The study reported only 4.8% of patients experienced severe adverse events, indicating safety and tolerability. TheraSphere is the only FDA-approved technology for unresectable HCC, paving the way for optimized treatment protocols.
Boston Scientific Corporation (NYSE: BSX) announced FDA approval for TheraSphere™ Y-90 Glass Microspheres to treat hepatocellular carcinoma (HCC). This approval enhances access to a therapy previously limited under humanitarian device exemptions. HCC is a prevalent cancer, with an estimated 32,000 new U.S. cases in 2021. Results from the LEGACY study demonstrated high response rates and overall survival, with 100% patient response seen after two treatments. The outpatient procedure reduces hospital burdens and aligns with recent NICE recommendations, indicating improved patient outcomes.
Boston Scientific (NYSE: BSX) has signed a definitive agreement to acquire Lumenis LTD.'s global surgical business for $1.07 billion. The deal, expected to close in the second half of 2021, includes Lumenis's innovations in energy-based medical solutions, specifically in urology and otolaryngology. With anticipated 2021 net sales of $200 million, the acquisition aims to enhance Boston Scientific's stone management offerings and expand its market presence in Europe and Asia. The impact on earnings per share is projected to be immaterial in 2021 but accretive starting in 2022.
Boston Scientific Corporation (NYSE: BSX) will participate in two investor conferences: the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, featuring CFO Dan Brennan and VP Susie Lisa, and the Cowen 41st Annual Health Care Conference on March 1, 2021, with SVP Meghan Scanlon and VP Susie Lisa. Each session will include a 30-minute Q&A segment. Live webcasts and replays will be available via the company's investor relations website.
Boston Scientific reported Q4 2020 net sales of $2.708 billion, showing a decline of (6.8)% compared to Q4 2019. GAAP net income available to common stockholders was $138 million or $0.10 EPS, significantly down from $3.996 billion or $2.83 EPS a year prior. For the full year 2020, sales totaled $9.913 billion, down (7.7)%. The transition to a consignment model for WATCHMAN customers impacted results negatively. The company received multiple FDA approvals and is planning growth for 2021 with projected revenue increases of 13% to 19%.
Boston Scientific Corporation has received FDA approval for the fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System, enhancing treatment options for over 10 million people globally with Parkinson's disease. This system includes Bluetooth-enabled, rechargeable, and non-rechargeable implantable pulse generators that work with Cartesia™ Directional Leads for optimal symptom relief. The company plans a controlled U.S. launch following its European debut in September 2020, potentially improving patient access and outcomes.
FAQ
What is the current stock price of Boston Scientific (BSX)?
What is the market cap of Boston Scientific (BSX)?
What does Boston Scientific Corp. specialize in?
What are the main segments of Boston Scientific?
What recent financial achievement has Boston Scientific announced?
What is the AGENT™ Drug-Coated Balloon (DCB)?
What is the focus of Boston Scientific’s latest clinical trials?
How has Boston Scientific performed financially in 2024?
What are some key products manufactured by Boston Scientific?
How much of Boston Scientific’s sales come from international markets?
Who are Boston Scientific’s customers?
What is Boston Scientific's vision for the future?
